Document is current

Article History

Received: 30 April 2024

Accepted: 21 August 2024

First Online: 10 September 2024

Declarations

:

: All procedures were carried out in accordance with the Declaration of Helsinki and were approved by the institutional review board of RTI International. Each participant provided informed consent.

: Not applicable.

: MJD and HRP are or were employees of Alkermes, Inc., at the time of the study and may own stock/options in the company. MB, CV, and CB are or were employees of RTI Health Solutions, a not-for-profit research institute that received funding from Alkermes, Inc., to conduct this study and collect the data used for this publication. LC consulted with Alkermes on this research and has served as a consultant for AbbVie/Allergan, Acadia, Adamas, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, MedAvante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda, and Wells Fargo, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; and speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, and Teva and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and universities and professional organizations/societies; owns stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, J&J, Merck, and Pfizer purchased >10 years ago and has stock options for Reviva; and has received royalties/publishing income from Elsevier (topic editor, <i>Psychiatry, Clinical Therapeutics</i>), Springer Healthcare (book), Taylor & Francis (editor-in-chief, <i>Current Medical Research and Opinion</i>, 2022-date), UpToDate (reviewer), and Wiley (editor-in-chief, <i>International Journal of Clinical Practice</i>, through end of 2019). MS consulted with Alkermes on this research and has served as a consultant to Janssen, Lundbeck, Neurelis, Otsuka, and Teva; has received research grants (within 3 years) from the US Centers for Disease Control and Prevention, International Society for Bipolar Disorders, National Institutes of Health, and Patient-Centered Outcomes Research Institute; has received royalties from Johns Hopkins University Press, Oxford Press, Springer Press, and UpToDate; and has prepared CME activities for the American Academy of Child and Adolescent Psychiatry, American Epilepsy Society, American Physician Institute (CMEtoGO), Clinical Care Options, Neurocrine, and Psychopharmacology Institute.